Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast

Oncogene
J M FlamanT Frebourg

Abstract

Recent studies have suggested that a rare class of p53 mutants found in tumours has a subtle transcriptional defect affecting bax induction but not p21 induction. We have therefore developed simple functional assays in yeast which can be used to identify these mutants. Analysis of 51 different mutations observed in human tumours showed that all mutants tested scored as mutant with the bax reporter strain but nine scored as wild-type with the p21 reporter strain. These results, which can be explained by the lower affinity of the p53 protein for the bax site, may suggest that p21 is not the key target of p53 mutations in tumours. Since p21 status has recently been shown to modulate the chemotherapeutic and radiotherapeutic sensitivities of cancerous cells, the functional assays described here may have important clinical implications.

Citations

Nov 24, 1999·International Journal of Cancer. Journal International Du Cancer·P O ChappuisR Iggo
Jul 13, 2007·Familial Cancer·Christian MonneratBrigitte Bressac-de Paillerets
Sep 24, 2002·International Journal of Radiation Oncology, Biology, Physics·Pierre MichelBernard Paillot
Apr 4, 2001·Cell Proliferation·R S Camplejohn, J Rutherford
Jul 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paola MontiGilberto Fronza
Apr 22, 2010·Molecular Cancer Research : MCR·Jennifer J JordanMichael A Resnick
Jul 18, 2002·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·T WongJ P Neoptolemos
Dec 18, 2004·Critical Reviews in Clinical Laboratory Sciences·Severine SeemannPierre Hainaut
May 13, 2006·Critical Reviews in Oncology/hematology·Benjamin Pierre BouchetCarlos María Galmarini
Sep 6, 2005·Differentiation; Research in Biological Diversity·Jana SmardováJana Koptíková
Aug 14, 2009·Clinical Chemistry and Laboratory Medicine : CCLM·Sébastien Van der VorstJean-Luc Gala
Sep 16, 1999·Biochemical and Biophysical Research Communications·P Chène
Aug 3, 1999·Japanese Journal of Cancer Research : Gann·T Kokunai, N Tamaki
Mar 22, 2018·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·Simin Mirakhor SamaniDaniel F Fouladi
Jun 27, 2002·British Journal of Cancer·J RutherfordR S Camplejohn
Feb 2, 2002·Nature Reviews. Molecular Cell Biology·Brian K Kennedy
Apr 13, 2012·EMBO Molecular Medicine·Luigi LeanzaIldikò Szabò
Mar 30, 2001·The Journal of Biological Chemistry·E C Thornborrow, J J Manfredi
Mar 16, 2004·The Journal of Biological Chemistry·Patricia S KhoQiang Yu
Sep 17, 2017·Oncotarget·Olivier BillantCécile Voisset
Sep 3, 2016·Oncotarget·Olivier BillantCécile Voisset
Jun 20, 2012·International Journal of Oncology·Jana JagosovaJana Smardova
Jul 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elisabetta MarangoniMarie-France Poupon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.